Cell Signaling Technology

Ermin (F4O7S) Rabbit Monoclonal Antibody

#18962 · $161

48
Citing papers
2.6k
Combined citations
Supplier page Find this product

Research areas

Myeloproliferative Neoplasms: Diagnosis and Treatment23Cytokine Signaling Pathways and Interactions21Eosinophilic Disorders and Syndromes8Chronic Myeloid Leukemia Treatments5MicroRNA in disease regulation5Kruppel-like factors research4Lymphoma Diagnosis and Treatment4Acute Myeloid Leukemia Research3

Papers citing this product

1
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Blood·2006·426 cit.·DOI
2
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
PLoS ONE·2006·215 cit.·DOI
3
Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations
Science·2020·189 cit.·DOI
4
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
Blood·2009·177 cit.·DOI
5
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Blood·2008·173 cit.·DOI
6
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
Leukemia·2007·169 cit.·DOI
7
Downregulation of miR-23a and miR-27a following Experimental Traumatic Brain Injury Induces Neuronal Cell Death through Activation of Proapoptotic Bcl-2 Proteins
Journal of Neuroscience·2014·156 cit.·DOI
8
Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent
Blood·2016·113 cit.·DOI
9
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia
Blood·2007·111 cit.·DOI
10
JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors
PLoS ONE·2010·85 cit.·DOI
Ermin (F4O7S) Rabbit Monoclonal Antibody — Evidence — PubIndex